Small molecule modulation of nuclear receptor conformational dynamics: Implications for function and drug discovery

Molecular Pharmacology

Volumn 83, Issue 1, 2013, Pages 1-8

  Kojetin, Douglas J ^a   Burris, Thomas P ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIDIABETIC AGENT; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MRL 24; PARTIAL AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SR 1664; UNCLASSIFIED DRUG;

ANISOTROPY; ANTIDIABETIC ACTIVITY; CRYSTAL STRUCTURE; DEUTERIUM HYDROGEN EXCHANGE; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE EXPRESSION; LIGAND BINDING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTON NUCLEAR MAGNETIC RESONANCE; SHORT SURVEY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PROTEIN CONFORMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84871541545     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.079285     Document Type: Short Survey

References (56)

1. Berger JP, Petro AE, and Macnaul KL et al. (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 17:662-676. (Pubitemid 36403578)
2. Bourguet W, Ruff M, Chambon P, Gronemeyer H, and Moras D (1995) Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 375:377-382.
3. Bruning JB, Chalmers MJ, Prasad S, Busby SA, Kamenecka TM, He Y, Nettles KW, and Griffin PR (2007) Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 15:1258-1271. (Pubitemid 47539157)
4. Bruning JB, Parent AA, and Gil G et al. (2010) Coupling of receptor conformation and ligand orientation determine graded activity. Nat Chem Biol 6:837 -843.
5. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, Öhman L, Greene GL, Gustafsson J-Å, and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758. (Pubitemid 27458965)
6. Chalmers MJ, Busby SA, Pascal BD, He Y, Hendrickson CL, Marshall AG, and Griffin PR (2006) Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. Anal Chem 78:1005-1014. (Pubitemid 43271829)
7. Chalmers MJ, Pascal BD, Willis S, Zhang J, Iturria SJ, Dodge JA, and Griffin PR (2011) Methods for the Analysis of High Precision Differential Hydrogen Deuterium Exchange Data. Int J Mass Spectrom 302:59-68.
8. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, and Rastinejad F (2008) Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature 456:350-356.
9. Choi JH, Banks AS, and Kamenecka TM et al. (2011a) Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477:477-481.
10. Choi JH, Banks AS, and Estall JL et al. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466:451-456.
11. Choi JH, Banks AS, and Kamenecka TM et al. (2011b) Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477:477-481.
12. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjöblom K, Karlsson U, Lindstedt EL, and Bamberg K (2001) Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9:699-706. (Pubitemid 32772892)
13. Dai SY, Burris TP, Dodge JA, Montrose-Rafizadeh C, Wang Y, Pascal BD, Chalmers MJ, and Griffin PR (2009) Unique ligand binding patterns between estrogen receptor alpha and beta revealed by hydrogen-deuterium exchange. Biochemistry 48:9668-9676.
14. Dai SY, Chalmers MJ, and Bruning J et al. (2008) Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method. Proc Natl Acad Sci USA 105:7171-7176. (Pubitemid 351754450)
15. Fernandes I and White JH (2003) Agonist-bound nuclear receptors: not just targets of coactivators. J Mol Endocrinol 31:1-7. (Pubitemid 37063074)
16. Frego L and Davidson W (2006) Conformational changes of the glucocorticoid receptor ligand binding domain induced by ligand and cofactor binding, and the location of cofactor binding sites determined by hydrogen/deuterium exchange mass spectrometry. Protein Sci 15:722-730.
17. Gampe RT, Jr, Montana VG, Lambert MH, Wisely GB, Milburn MV, and Xu HE (2000) Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. Genes Dev 14:2229-2241.
18. Hamuro Y, Coales SJ, Morrow JA, Molnar KS, Tuske SJ, Southern MR, and Griffin PR (2006) Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators. Protein Sci 15:1883-1892. (Pubitemid 44141506)
19. Hoofnagle AN, Resing KA, and Ahn NG (2003) Protein analysis by hydrogen exchange mass spectrometry. Annu Rev Biophys Biomol Struct 32:1-25. (Pubitemid 37056219)
20. Hughes TS, Chalmers MJ, and Novick S et al. (2012) Ligand and receptor dynamics contribute to the mechanism of graded PPARg agonism. Structure 20:139-150.
21. Johnson BA, Wilson EM, Li Y, Moller DE, Smith RG, and Zhou G (2000) Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol 298:187-194.
22. Kallenberger BC, Love JD, Chatterjee VK, and Schwabe JW (2003) A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nat Struct Biol 10:136-140. (Pubitemid 36177095)
23. Kojetin DJ, Burris TP, Jensen EV, and Khan SA (2008) Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor. Endocr Relat Cancer 15:851-870.
24. Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, Kamenecka TM, and Griffin PR (2012) Identification of SR2211: A potent synthetic RORgamma-selective modulator. ACS Chem Biol 20:672-677.
25. Lee G, Elwood F, and McNally J et al. (2002) T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 277:19649-19657. (Pubitemid 34967479)
26. Leesnitzer LM, Parks DJ, and Bledsoe RK et al. (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640-6650. (Pubitemid 34547354)
27. Lu J, Cistola DP, and Li E (2006) Analysis of ligand binding and protein dynamics of human retinoid X receptor alpha ligand-binding domain by nuclear magnetic resonance. Biochemistry 45:1629-1639. (Pubitemid 43222107)
28. Malapaka RR, Khoo S, and Zhang J et al. (2012) Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J Biol Chem 287:183-195.
29. Matthews J and Gustafsson J-Å (2003) Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3:281-292.
30. Motani A, Wang Z, and Weiszmann J et al. (2009) INT131: a selective modulator of PPAR gamma. J Mol Biol 386:1301-1311.
31. Nagy L and Schwabe JW (2004) Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci 29:317-324. (Pubitemid 38968764)
32. Nettles KW, Bruning JB, and Gil G et al. (2008) NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol 4:241-247. (Pubitemid 351414832)
33. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, and Milburn MV (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137-143. (Pubitemid 28425645)
34. Pike AC, Brzozowski AM, and Hubbard RE (2000a) A structural biologist's view of the oestrogen receptor. J Steroid Biochem Mol Biol 74:261-268. (Pubitemid 32140404)
35. Pike ACW (2006) Lessons learnt from structural studies of the oestrogen receptor. Best Pract Res Clin Endocrinol Metab 20:1-14.
36. Pike ACW, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engström O, Ljunggren J, Gustafsson J-Å, and Carlquist M (1999) Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 18:4608-4618. (Pubitemid 29415516)
37. Pike ACW, Brzozowski AM, Walton J, Hubbard RE, Bonn T, Gustafsson J-Å, and Carlquist M (2000b) Structural aspects of agonism and antagonism in the oestrogen receptor. Biochem Soc Trans 28:396-400.
38. Pike ACW, Brzozowski AM, Walton J, Hubbard RE, Thorsell AG, Li Y-L, Gustafsson J-Å, and Carlquist M (2001) Structural insights into the mode of action of a pure antiestrogen. Structure 9:145-153. (Pubitemid 32215278)
39. Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, Burris LL, Khorasanizadeh S, Burris TP, and Rastinejad F (2007) Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat Struct Mol Biol 14:1207-1213. (Pubitemid 350223341)
40. Savkur RS and Burris TP (2004) The coactivator LXXLL nuclear receptor recognition motif. J Pept Res 63:207-212. (Pubitemid 38496672)
41. Shang Y and Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468. (Pubitemid 34270263)
42. Shang Y, Hu X, DiRenzo J, Lazar MA, and Brown M (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852.
43. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, and Greene GL (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937. (Pubitemid 29019045)
44. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, and Greene GL (2002) Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 9:359-364. (Pubitemid 34462554)
45. Solt LA, Kumar N, and Nuhant P et al. (2011) Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472:491-494.
46. Solt LA, Wang Y, and Banerjee S et al. (2012) Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 485:62-68.
47. Tamrazi A, Carlson KE, and Katzenellenbogen JA (2003) Molecular sensors of estrogen receptor conformations and dynamics. Mol Endocrinol 17:2593-2602. (Pubitemid 37542220)
48. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, and Berkenstam A (1998) Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J Biol Chem 273:31108-31112. (Pubitemid 28533120)
49. Wright E, Busby SA, Wisecarver S, Vincent J, Griffin PR, and Fernandez EJ (2011) Helix 11 dynamics is critical for constitutive androstane receptor activity. Structure 19:37-44.
50. Yan X, Broderick D, Leid ME, Schimerlik MI, and Deinzer ML (2004) Dynamics and ligand-induced solvent accessibility changes in human retinoid X receptor homodimer determined by hydrogen deuterium exchange and mass spectrometry. Biochemistry 43:909-917. (Pubitemid 38141488)
51. Yan X, Deinzer ML, Schimerlik MI, Broderick D, Leid ME, and Dawson MI (2006) Investigation of ligand interactions with human RXRalpha by hydrogen/deuterium exchange and mass spectrometry. J Am Soc Mass Spectrom 17:1510-1517. (Pubitemid 44635271)
52. Yan X, Pérez E, Leid M, Schimerlik MI, de Lera AR, and Deinzer ML (2007) Deuterium exchange and mass spectrometry reveal the interaction differences of two synthetic modulators of RXRalpha LBD. Protein Sci 16:2491-2501. (Pubitemid 350036754)
53. Yin L, Wu N, and Curtin JC et al. (2007) Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways. Science 318:1786-1789. (Pubitemid 350274391)
54. Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Garcia-Ordonez RD, Pascal BD, Burris TP, Dodge JA, and Griffin PR (2010) Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer. Structure 18:1332-1341.
55. Zhang J, Chalmers MJ, and Stayrook KR et al. (2011) DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat Struct Mol Biol 18:556-563.
56. Zhao C, Dahlman-Wright K, and Gustafsson JA (2008) Estrogen receptor beta: an overview and update. Nucl Recept Signal 6:e003.